Germany’s Melanoma market size stood at around USD XX.X billion in 2019 and is projected to reach USD XX billion by 2028, exhibiting a CAGR of around 7.4% during the forecast period.
Germany is one of the largest markets for melanoma cancer diagnostics in Europe. Rapid melanoma treatment market growth is anticipated over the forecast period due to the expanding melanoma treatment population and the continued uptake of recently approved drugs.
The melanoma pipeline is currently strong, with several promising molecules in development including, Polynoma’s seviprotimut-L, Amgen’s talimogene laherparepvec (T-VEC) and Roche and Genentech’s cobimetinib in combination with Zelboraf, which are in development for Cutaneous Melanoma, as well as AstraZeneca’s selumetinib which is in development for Ocular Melanoma.
Increase in melanoma cases, presence of effective immunotherapies acts as primary market drivers for Germany melanoma market. Furthermore, Government initiatives aided for that growth, and Technological advancements & increasing R&D on cancer diagnosis and management fueled the market.